Lexeo Therapeutics (NASDAQ:LXEO) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Lexeo Therapeutics (NASDAQ:LXEO) released its quarterly earnings data on Monday. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04, FiscalAI reports.

Lexeo Therapeutics Stock Performance

Shares of LXEO stock opened at $6.12 on Tuesday. The company has a market cap of $480.54 million, a P/E ratio of -2.79 and a beta of 1.52. The stock has a 50 day simple moving average of $6.22 and a two-hundred day simple moving average of $7.77. Lexeo Therapeutics has a fifty-two week low of $2.43 and a fifty-two week high of $10.99.

Insiders Place Their Bets

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $5.69, for a total value of $312,950.00. Following the completion of the sale, the chief executive officer directly owned 340,106 shares in the company, valued at approximately $1,935,203.14. The trade was a 13.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 68,189 shares of company stock valued at $397,156 in the last ninety days. Insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of hedge funds have recently added to or reduced their stakes in LXEO. California State Teachers Retirement System increased its holdings in Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after purchasing an additional 2,148 shares in the last quarter. Cerity Partners LLC bought a new stake in Lexeo Therapeutics in the second quarter worth approximately $50,000. Russell Investments Group Ltd. increased its holdings in Lexeo Therapeutics by 160.2% in the fourth quarter. Russell Investments Group Ltd. now owns 5,872 shares of the company’s stock worth $58,000 after purchasing an additional 3,615 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Lexeo Therapeutics in the first quarter valued at approximately $85,000. Finally, Scientech Research LLC acquired a new stake in Lexeo Therapeutics in the third quarter valued at approximately $90,000. 60.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on LXEO shares. Weiss Ratings lowered Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Wall Street Zen lowered Lexeo Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Chardan Capital reissued a “buy” rating and set a $17.00 price target on shares of Lexeo Therapeutics in a research note on Monday. Finally, HC Wainwright cut their price target on Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.88.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.